---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-218611"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T01:08:07.280291+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# IO Biotech reports Q2 net loss of $18.5M; cash $170.1M to fund data readouts into mid-2024

## Summary
- Net loss $18.5M for Q2 2022 vs $38.4M in Q2 2021, driven by higher R&D and G&A costs.
- R&D expenses $12.2M (up from $6.7M) due to Phase 3 trial initiation and increased headcount.
- Cash and equivalents $170.1M at June 30, 2022, down from $211.5M at Dec 31, 2021.
- Initiated Phase 3 IOB-013/KN-D18 trial of IO102-IO103 + pembrolizumab in advanced melanoma.
- Phase 2 basket trial (IOB-022/KN-D38) dosing started; preliminary data expected H2 2022.

## SEC filing metadata
- accession: 0001193125-22-218611
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312522218611/0001193125-22-218611-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312522218611/d359264d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-218611
- JSON: https://secwatch.observer/filing/0001193125-22-218611.json
- Plain text: https://secwatch.observer/filing/0001193125-22-218611.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.